Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1582-1587

  Mentrikoski, Mark J ^a   Ma, Linglei ^b   Pryor, Jennifer G ^a   McMahon, Loralee A ^a   Yang, Qi ^a   Spaulding, Betsy O ^c   Scott, Glynis A ^a   Wang, Hanlin L ^d   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c AGILENT TECHNOLOGIES   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

IMP3; Melanoma; Metastatic melanoma; Nodal nevus; Sentinel lymph node

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN IMP3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; NEVUS; PREDICTIVE VALUE OF TESTS; RNA-BINDING PROTEINS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 71149103690     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.128     Document Type: Article

References (30)

1. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
2. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
3. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
4. Stewart FW, Doan CA. An analysis of the lymphadeno-pathy question with special reference to Hodgkin's disease tuberculosis. Ann Surg 1931;93:141-152.
5. Ridolfi RL, Rosen PP, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 1977;39:164-171.
6. McCarthy SW, Palmer AA, Bale PM, et al. Nevus cells in lymph nodes. Pathology 1974;6:351-358.
7. Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 1994;102:102-108.
8. Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996;20: 834-840.
9. Murray CA, Leong WL, McCready DR, et al. Histo-pathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol 2004;57:64-67.
10. Fontaine D, Parkhill W, Greer W, et al. Nevus cells in lymph nodes: an association with congenital cutaneous nevi. Am J Dermatopathol 2002;24:1-5.
11. Holt JB, Sangueza OP, Levine EA, et al. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am J Clin Pathol 2004;121:58-63.
12. Fisher CJ, Hill S, Millis RR. Benign lymph node inclusions mimicking metastatic carcinoma. J Clin Pathol 1994;47:245-247.
13. Hruban RH, Eckert F, Baricevic B. Melanocytes of a melanocytic nevus in a lymph node from a patient with a primary cutaneous melanoma associated with a small congenital nevus. Am J Dermatopathol 1990;12: 402-407.
14. Biddle DA, Evans HL, Kemp BL, et al. Intraparench-ymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol 2003;27:673-681.
15. Pryor JG, Bourne PA, Yang Q, et al. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 2008;21:431-437.
16. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005;280: 18517-18524.
17. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729-2733.
18. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-1270.
19. Hammer NA, Hansen TO, Byskov AG, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005;130:203-212.
20. Simon R, Bourne PA, Yang Q, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 2007;38: 1178-1183.
21. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 2004;24: 671-678.
22. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005;29:188-195.
23. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003;88:887-894.
24. Xu H, Bourne PA, Spaulding BO, et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007;38:555-563. (Pubitemid 46399894)
25. Lohmann CM, Iversen K, Jungbluth AA, et al. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am J Surg Pathol 2002;26: 1351-1357.
26. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, et al. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer 2004;100:1683-1691.
27. Kucher C, Zhang PJ, Acs G, et al. Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma? Appl Immunohistochem Mol Morphol 2006;14:324-327.
28. Mahmood MN, Lee MW, Linden MD, et al. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells. Mod Pathol 2002;15:1288-1293.
29. Zubovits J, Buzney E, Yu L, et al. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol 2004;35:217-223.
30. Scolyer RA, Murali R, Satzger I, et al. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol 2008;17:165-174.